Idera Pharmaceuticals, Inc. (IDRA) 10-K Annual Report March 2022

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2021	Mar. 31, 2022	Jun. 30, 2021
Document and Entity Information
Document Type	10-K
Document Period End Date	Dec. 31, 2021
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-31918
Entity Registrant Name	IDERA PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3072298
Entity Address, Address Line One	505 Eagleview Blvd., Suite 212
Entity Address, City or Town	Exton
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19341
City Area Code	484
Local Phone Number	348-1600
Title of 12(b) Security	Common Stock, $.001 par value
Trading Symbol	IDRA
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
ICFR Auditor Attestation Flag	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		52,924,870
Entity Public Float			$ 63.8
Entity Central Index Key	0000861838
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Amendment Flag	false
Auditor Firm ID	42
Auditor Name	ERNST & YOUNG LLP
Auditor Location	Philadelphia, Pennsylvania

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/861838/000155837022004903/idra-20211231x10k.htm

View differences made from one year to another to evaluate Idera Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Idera Pharmaceuticals, Inc..

Continue

Assess how Idera Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Idera Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter Sentiment:

All

Positive

Negative

Filter Category:

All

Financial

Revenue

M & A

Other

Filter Subcategory:

All

Expense

Geography

Product

Other

Inside Idera Pharmaceuticals, Inc.'s 10-K Annual Report:

Financial - Expense Highlight
Restructuring costs for the year ended December 31, 2021 totaled approximately $1.3 million and is comprised of termination costs including severance, benefits and related costs.

Financial - Expense Highlight
The decrease of the research and development expenses is offset by the costs associated with ILLUMINATE-206 and the Scriptr Agreement.
Revenue - Geography Highlight
We filed a shelf registration statement on Form S-3 on August 4, 2020, which was declared effective on September 2, 2020, relating to the sale, from time to time, in one or more transactions, up to $150.0 million of common stock, preferred stock, depository shares and warrants.
Financial - Expense Highlight
This decrease is primarily related to: (i) costs incurred with contract research organizations during the year ended December 31, 2021 to support our ILLUMINATE-301 trial, which was discontinued by the Company in the second quarter of 2021; and (ii) lower costs incurred with drug manufacturing activities.
Financial - Expense Highlight
During the fiscal year ended December 31, 2021, our overall research and development expenses declined by 34% as compared to 2020, primarily due to decreases in external development costs associated with tilsotolimod (IMO-2125).
Other - Other
We regard an accounting estimate...Read more
Financial - Expense
In addition, increases in expenses...Read more
Financial - Shares
LPC Purchase Agreement On March...Read more
Financial - Expense
Restructuring Costs In April 2021,...Read more
Financial - Expense
In connection with these actions,...Read more
Financial - Shares
ATM Agreement In November 2018,...Read more
Financial - Expense
If factors change and we...Read more
Other - Other
Warrant Revaluation Gain or Loss...Read more
Other - Other
Future Tranche Right Revaluation Gain...Read more
Other - Other
We believe based on our...Read more
Financial - Shares
As of March 31, 2022,...Read more
M & A - Other
Our current focus is to...Read more
Financial - Shares
Warrant and Future Tranche Right...Read more
Revenue - Product
Historically, we have funded our...Read more
Other - Other
The decrease in 2021, as...Read more
Other - Other
Due to the nature of...Read more
Financial - Expense
We commenced clinical development of...Read more
Financial - Expense
We do not allocate indirect...Read more
Other - Other
These fluctuations may be due...Read more
Financial - Shares
Additionally, the December 2019 Securities...Read more
Financial - Expense
Some CROs invoice us on...Read more
Financial - Expense
Research and Development Prepayments, Accruals...Read more
Other - Other
In December 2021, we announced...Read more
Other - Other
Amounts may fluctuate from period...Read more
Other - Other
We determine the estimates of...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Idera Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: IDRA
CIK: 861838
Form Type: 10-K Annual Report
Accession Number: 0001558370-22-004903
Submitted to the SEC: Thu Mar 31 2022 4:06:21 PM EST
Accepted by the SEC: Thu Mar 31 2022
Period: Friday, December 31, 2021
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/idra/0001558370-22-004903.htm

Idera Pharmaceuticals, Inc. (IDRA) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

SEC Filings

IDRA Valuations

IDRA Annual Reports

IDRA Quarterly Reports

IDRA Corporate News